Stay updated on Clinical Trial: Osi+Sav in EGFRm+/MET+ NSCLC Post-Osi

Sign up to get notified when there's something new on the Clinical Trial: Osi+Sav in EGFRm+/MET+ NSCLC Post-Osi page.
Latest website image capture
Clouds background image

Latest updates to the Clinical Trial: Osi+Sav in EGFRm+/MET+ NSCLC Post-Osi page

  1. Check
    yesterday
    No Change Detected
  2. Check
    8 days ago
    Change Detected
    Summary
    Added and updated the Locations sections to include California, District of Columbia, Maryland, Massachusetts, Minnesota, New York, Pennsylvania, Washington, and Alberta/Ontario; removed the prior state-location entries and the HHS Vulnerability Disclosure link.
    Difference
    0.6%
    Check dated 2025-12-24T14:36:17.000Z thumbnail image
  3. Check
    15 days ago
    No Change Detected
  4. Check
    23 days ago
    No Change Detected
  5. Check
    30 days ago
    Change Detected
    Summary
    Publications section added: Savolitinib Plus Osimertinib in Epidermal Growth Factor-Mutated, MET-Amplified Advanced Non-Small Cell Lung Cancer: A Randomized Phase II trial. This update does not alter the study design, eligibility criteria, endpoints, or enrollment.
    Difference
    0.0%
    Check dated 2025-12-02T17:57:23.000Z thumbnail image
  6. Check
    37 days ago
    Change Detected
    Summary
    The Publications section now states entries are automatically filled from PubMed and may not all pertain to the study, and the revision tag changed from v3.2.0 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-11-25T14:50:04.000Z thumbnail image
  7. Check
    44 days ago
    Change Detected
    Summary
    Removed the government funding/status notice that warned about potential delays and operating status. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2025-11-18T07:31:55.000Z thumbnail image
  8. Check
    51 days ago
    Change Detected
    Summary
    Replaced the Taiwan site entry 'Tainan City, Taiwan, 70403' with 'Tainan, Taiwan, 70403'.
    Difference
    0.0%
    Check dated 2025-11-11T03:30:20.000Z thumbnail image
  9. Check
    66 days ago
    Change Detected
    Summary
    The new screenshot shows only minor cosmetic/UI adjustments to the Study Details page, with no changes to core data such as eligibility criteria, primary/secondary outcomes, enrollment, or location. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2025-10-27T21:10:04.000Z thumbnail image

Stay in the know with updates to Clinical Trial: Osi+Sav in EGFRm+/MET+ NSCLC Post-Osi

Enter your email address, and we'll notify you when there's something new on the Clinical Trial: Osi+Sav in EGFRm+/MET+ NSCLC Post-Osi page.